Etoposide

Catalog No.S1225 Synonyms: VP-16, VP-16213

Etoposide Chemical Structure

Molecular Weight(MW): 588.56

Etoposide is a semisynthetic derivative of podophyllotoxin, which inhibits DNA synthesis via topoisomerase II inhibition activity.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 280 In stock
USD 690 In stock
USD 990 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • ABT-199 synergizes strongly with lymphoma chemotherapy agents that affect MCL1 levels. Viability and CI vs Fa after 24-h exposure to etoposide alone or in combination with ABT-199 in Riva, U2932 and VavP-Bcl2/c-MYC murine tumor cells. Viability shown at 500 nM.

    Leukemia, 2015, 29: 1702–1712. Etoposide purchased from Selleck.

    Dox promotes formation of DNA DSBs in primary neurons. (A) Cortical neurons at 28–32 DIV were treated with a vehicle or with Dox (0.1 μ M) or with DNA damaging drug etoposide (5 μ M) overnight, fixed, and stained for a marker of DSBs phosphorylated histone H2A variant X, γ H2A.X (green), MAP2c (red), and with the nuclear Hoechst dye (blue), and imaged. The neuronal nucleus is enlarged on the Dox panel to illustrate the γ H2A.X puncta. Note the green nuclear staining in cells treated with Dox and etoposide. Also note the reduced dendritic arborization in neurons treated with Dox and etoposide. Scale bar is 20 μm.

    Sci Rep, 2016, 6:25705.. Etoposide purchased from Selleck.

  • Viability of U87 cells(C) assessed by the Alamar blue assay, 72 h after transfection with siRNA anti-survivin (siSURV) or with siMUT and/or cell incubation with the chemotherapeutical drugs etoposide (ETO) and Bliss interaction index (D) determined for the combined effects on cell viability of survivin silencing plus treatment with each drug. Cells were transfected, for 4 h, with (14Ser)2N5/siRNA/HL complexes and, after an additional period of 20 h, cells were incubated with 1.5 μM ETO (C) for 48 h. Results, representative of at least three independent experiments, are expressed as a percentage of the nontreated control cells. Combined treatment (dotted bar) was compared with the single drug treatment (gray bar) (**p < 0.01, ***p < 0.001) and the Bliss interaction index of each combined treatment was compared with the theoretical value expected for an additive effect (1.0) (#p < 0.05, ns, non-significant).

    Eur J Pharm Biopharm, 2016, 104:7-19.. Etoposide purchased from Selleck.

    Cellular biomarker responses in HT29 cells exposed to various cytotoxic chemotherapeutic agents in combination with the Chk1 inhibitor V158411. HT29 cells were exposed to the combination GI80 of gemcitabine (0.2 uM), camptothecin (0.44 uM), cisplatin (68 uM), oxaliplatin (131 uM), doxorubicin (1.2 uM) or etoposide (59 uM) for 18 hours followed by DMSO (-) or 400 nM V158411 (+) for a further 24 hours. Protein expression was characterized by immunoblotting.

    BMC Cancer 2014 14, 483. Etoposide purchased from Selleck.

  • (c) and (d) Effects of fractions C4 and C5 on topoisomerase II activity. Topoisomerase II activity was measured by plasmid DNA cleavage assay. DNA bands were visualized using UV light and the intensity of linear DNA band in each lane was measured using imageJ software. Lane 1: plasmid PBR322DNA. Lane 2: control, topoisomerase II + plasmid PBR322DNA. Lanes 3, 4, and 5: 40, 20, and 10 μg/mL fraction C4 + plasmid PBR322DNA, respectively. Lanes 6, 7, and 8: 40, 20, and 10 μg/mL fraction C5 + plasmid PBR322DNA, respectively. Lane 9: 100 μM etoposide + plasmid PBR322DNA. The data in different groups were expressed as the mean ± SD from 3 experiments. Statistical difference between groups was assessed by t-test using SPSS 20.0. ∗∗P < 0.01 versus the control group.

    Evid Based Complement Alternat Med, 2017, 2017:1456786. Etoposide purchased from Selleck.

Purity & Quality Control

Choose Selective Topoisomerase Inhibitors

Biological Activity

Description Etoposide is a semisynthetic derivative of podophyllotoxin, which inhibits DNA synthesis via topoisomerase II inhibition activity.
Targets
Topo II [2]
(Cell-free assay)
In vitro

Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA, which induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. [1] Etoposide inhibits the growth of murine angiosarcoma cell line (ISOS-1) in a 5 days-period with IC50 of 0.25 μg/mL. Cell growth of normal murine microvascular endothelial cells (mECs) is less sensitive to Etoposide with IC50 of 10 μg/mL). [2] Etoposide treated for 6 hr inhibits colonies of tetraploid variant of the human leukemic lymphoblast line CCRF-CEM with IC50 of 0.6 μM. [3] Etoposide treated for 2 hr inhibits growth of human pancreatic cancer cell line Y1, Y3, Y5, Y19, YM. YS, and YT with IC50s of 300 μg/mL, 300 μg/mL, 300 μg/mL, 91 μg/mL, 0.68 μg/mL, 300 μg/mL, 300 μg/mL, and 260 μg/mL, respectively. [4] Etoposide exposed for 1 hr inhibits growth of human glioma cell lines CL5, G142, G152, G111, and G5 with IC50 of 8, 9, 9.8, 10, and 15.8 μg/mL respectively for 12 days. Under same condition, the IC90 value is attained in cell lines CL5, G152, G142, and G111 at 26, 27, 32, and 33 μg/mL. Etoposide inhibition of topoisomerase II is homogeneous for each cell. The average inhibition rates are 15%, 21.8%, 31.8%, 41.5%, and 49.5% for 1, 2, 4, 8, and 16 μg Etoposide, respectively. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kelly M3n2RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrX[HNKSzVyPUCuNVLjiIoEsfMAjVAvODFizszN M4fMV|I2QTZyMkiy
KellyCis83 M2jjfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LHbGlEPTB;MD6xOwKBkcLz4pEJNE4xOiEQvF2= MoPuNlU6PjB{OEK=
SK-N-AS NW\uOpFQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXpbnZKSzVyPUCuNlTjiIoEsfMAjVAvODNizszN NWPxNWpROjV7NkCyPFI>
SK-N-ASCis24 M2TNfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fRbGlEPTB;MD61O-KBkcLz4pEJNE4yOSEQvF2= M17tV|I2QTZyMkiy
U87 Mmr0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLPNE02OCEQvF2= NX3SUFF4PDhiaB?= NH;Qc2Zl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImge4hq[2hiY3HuJIJmKGWwaHHuZ4VlKGK7IIPpcIljcW6rbh?= NGi0fYkzPTd3MEK3Ny=>
HCT116 M33adWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHo[GsxNjVvMj61JO69VQ>? MWG0POKhcMLi M1y4R2lEPTB;MT63N:KhyrIEoECuNlHDqM7:TR?= M3LsVFI2PzR4N{[z
HT-29 NE\tPHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYSwMlUuOi53IN88US=> MmPLOFjDqGkEoB?= MWjJR|UxRTdwMtMgxtHDqDFwMEVCpO69VQ>? Mni4NlU4PDZ5NkO=
Caco2 MnztS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;LNE42NTJwNTFOwG0> MUi0POKhcMLi NFPPXZZKSzVyPUeuNlbDqMLzwrCxMlY5yqEQvF2= M3jtfFI2PzR4N{[z
COLO 205 M3vtOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrENE42NTJwNTFOwG0> M{PnRlQ5yqCqwrC= NEDvcZlKSzVyPUGuOlHDqMLzwrCwMlAzyqEQvF2= M1rQOVI2PzR4N{[z
SW480 NH7SVG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rrOlAvPS1{LkWg{txO M3v5UVQ5yqCqwrC= NHvWeHpKSzVyPUSuPVLDqMLzwrCwMlM{yqEQvF2= NVjUZZdSOjV5NE[3OlM>
HEK293T MlviS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVi2TYlXOS13IN88US=> M3LJZlQ5yqCqwrC= M3P5V2lEPTB;Mj60NuKhyrIEoECuNFXDqM7:TR?= NVPwWHZIOjV5NE[3OlM>
Hep3B  MVfGeY5kfGmxbjDBd5NigQ>? MkToNVAh|ryP M{DFWVQ5yqCqwrC= NIfm[pJz\WS3Y3XzJJRp\SCnbnjhcoNqdmdiZX\m[YN1KG:oIFLNVE03 MYiyOVY{OzV4NB?=
Hep3B  NFP0WmJHfW6ldHnvckBCe3OjeR?= M4P4XVAvOS1zMDFOwG0> MljrNlQhcA>? NHzlOGR{fXCycnXzd4V{KHSqZTDlfJBz\XO|aX;uJI9nKGincHPp[IlvKG2UTlG= NHPZelUzPTZ|M{W2OC=>
HEK293 NYDGXm9[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rld2lEPTB;Nz6xOOKhyrIEoECuN|bDqM7:TR?= MoXuNlU3ODNzMkK=
DU145 MmLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXKVXZKSzVyPUKuNljDqMLzwrCwMlA1yqEQvF2= MnvmNlU3ODNzMkK=
HCT15 NVfPW5J[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFuwOZlKSzVyPUCuPFHDqMLzwrCwMlAyyqEQvF2= M4j3RVI2PjB|MUKy
T47D MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW[4Sm5wUUN3ME2zMlE5yqEEsdMgNE4yOcLizszN Mkj0NlU3ODNzMkK=
SMMC-7721 MVTGeY5kfGmxbjDBd5NigQ>? M3zUNVQxKM7:TR?= MmX6OFghcA>? NFT0N2pFVVOR Mor5bY5lfWOnczFOt2gzSVhiZn;jbUBnd3KvYYTpc44> NU\Cb45ROjV3NESzOlE>
MDA-MB-231 M{fCWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVK3NuKhcA>? M2rvZmlEPTB;MkGuNuKhyrIEoESuNuKh|ryP NILkOVQzPTR6NkKxPS=>
MCF-7 NY\hXVN4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmn3O|LDqGh? NFrNPJJKSzVyPUGwMlnDqMLzwrCyMlHDqM7:TR?= Mn;1NlU1QDZ{MUm=
Jurkat M4LiU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX[3NuKhcA>? MmXBTWM2OD1zLkNCpOKyyqBzLkZCpO69VQ>? MmLHNlU1QDZ{MUm=
HeLa MknKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jXelczyqCq MljJTWM2OD1|LkpCpOKyyqB{LkRCpO69VQ>? MXOyOVQ5PjJzOR?=
MCF7  Mnf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTCOU0yODBizszN NWrTc5htPyCm MmrmbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NX7rVHFZOjV2N{K2NVk>
K562 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjEe5Y4OsLiaB?= NGm0dZNKSzVyPUCuNlnDqM7:TR?= NHnDZWUzPTJ6Mk[1Ny=>
K/VP.5 M{\BSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLQO|LDqGh? NED5fGlKSzVyPUSuPeKh|ryP NETUR48zPTJ6Mk[1Ny=>
SH-EP  MWLGeY5kfGmxbjDBd5NigQ>? NGnGWGIzOMLizsznM41t M1HucVI1yqCq NVnu[o1kcW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nKGWwZH;n[Y5wfXNiRFXQVC=> M1rGSlI2OjZzOUix
SCC25 MoC2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWOyOOKhcA>? NXPsbG5OUUN3ME20N{4{yqEEsdMgNU4yOsLizszN NEXZWHUzPTJ{MEeyPS=>
CAL27 MmK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TZZlI1yqCq NY\vNYtCUUN3ME21Nk4yyqEEsdMgNU4xQcLizszN MUCyOVIzODd{OR?=
FaDu MlyxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1X1bFI1yqCq M{HXRWlEPTB;MkWuPFnDqMLzwrCxMlE{yqEQvF2= M3\UNlI2OjJyN{K5
SCC25 M3HGNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVu0POKhcA>? MmLhTWM2OD1{MD64OuKhyrIEoEGuNFfDqM7:TR?= NHf1dWkzPTJ{MEeyPS=>
CAL27 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmC0OFjDqGh? NIjHV3BKSzVyPUG4MlI1yqEEsdMgNU4yPcLizszN NV\QTJh{OjV{MkC3Nlk>
FaDu M4TMU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPxTlU1QMLiaB?= MlT1TWM2OD14LkSzxsDDucLiMT6xN:Kh|ryP MY[yOVIzODd{OR?=
SCC25 NXHPR4xuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVH6W3h4PzMEoHi= MYTJR|UxRThwNEJCpOKyyqBzLkGxxsDPxE1? NUj6TJdwOjV{MkC3Nlk>
CAL27 M4fXc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jFS|czyqCq NH2ydGlKSzVyPUSuNlfDqMLzwrCxMlE1yqEQvF2= NIXOR2szPTJ{MEeyPS=>
FaDu NEjDeHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXq3NuKhcA>? MVLJR|UxRTVwMENCpOKyyqBzLkG1xsDPxE1? NFHCTIozPTJ{MEeyPS=>
MCF-7 NVXtcXhuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjVOpRCPDkEoHlCpC=> MmjuSG1UVw>? M{C5d2lEPTB;Nz6yxsDDucLiMD64xsDPxE1? NGjLOVgzPTJzNkO3PC=>
T-47D M4jHNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nN[|Q5yqCqwrC= M{T2W2ROW09? Mn7RTWM2OD15LkhCpOKyyqByLkhCpO69VQ>? MXGyOVIyPjN5OB?=
MDA-MB-231 Mlr1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mni4OFjDqGkEoB?= M1TB[GROW09? MnLqTWM2OD1zMj64xsDDucLiMT6wxsDPxE1? M4niT|I2OjF4M{e4
DU145 NUG0THNISXCxcITvd4l{KEG|c3H5 MmfnNVAuOTByIN88US=> M1X1b|ghcA>? MYDEUXNQ M3GyPYlv\HWlZYOgZ4VtdCCmZXH0bEB{cWewaX\pZ4FvfGy7IHnuJIEhfmW{eTDsc5ch[2:wY3XueJJifGmxbh?= NILKbIQzPTF2OU[4NS=>
DU145 stem-like NW\PZ2ZkSXCxcITvd4l{KEG|c3H5 NWHnNYFYOTBvMUCwJO69VQ>? NGm3SXk5KGh? Ml3JSG1UVw>? NF\icWlqdmS3Y3XzJINmdGxiZHXheIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MV6yOVE1QTZ6MR?=
DU145 M4[3XGZ2dmO2aX;uJGF{e2G7 M33pdlExNTFyMDFOwG0> MVuyJIg> NXvuU3pHTE2VTx?= NW\C[HFicW6lcnXhd4V{KHSqZTDwR2hMOSCneIDy[ZN{cW:wIHHu[EBl\WO{ZXHz[ZMhfGinIIDDTGsyKGW6cILld5Nqd25iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M2KxdlI2OTR7Nkix
DU145 stem-like NHzIcHRHfW6ldHnvckBCe3OjeR?= MVyxNE0yODBizszN NIrvOYkzKGh? M2LFZmROW09? M2PJe4lv[3KnYYPld{B1cGVicFPIT|Eh\XiycnXzd4lwdiCjbnSg[IVkemWjc3XzJJRp\SCyQ1jLNUBmgHC{ZYPzbY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MUSyOVE1QTZ6MR?=
UW228-3 NEm3NZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEG2c|MxNjBzLUOwNEDPxE1? Ml7BOFghcA>? NXjO[ZR6TE2VTx?= NV\ad3JPUUN3ME2wMlk6yqEQvF2= M4\S[|I2OTF7MUi1
NSCs M{nWPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\5W|ExNjBzLUOwNEDPxE1? MoPmOFghcA>? NYrC[Y8yTE2VTx?= MnrmTWM2OD1yLkOtN:Kh|ryP MWGyOVEyQTF6NR?=
MKL-1  MXHGeY5kfGmxbjDBd5NigQ>? MXOxNE0yODByIH7N NYTYeItnPCCm MkPpbY5lfWOnczD0bIUhcW6mdXP0bY9vKG:oIF3IR{1KKGW6cILld5Nqd25? NUPkOJJ5OjVzMU[3OVQ>
MCF7 EV M1rPbGZ2dmO2aX;uJGF{e2G7 MkfoNVAuOTByIN88US=> NWnRVWpDOuLCiXi= MlHubY5lfWOnczDwdo9lfWO2aX;uJI9nyqEQs1iyRXg> NHzMclYzPTB6OEKwNy=>
MCF 7BMI1 MVXGeY5kfGmxbjDBd5NigQ>? NVLVPXYxOTBvMUCwJO69VQ>? M{fI[lLjiImq MlXCbY5lfWOnczDwdo9lfWO2aX;uJI9nyqEQs1iyRXg> MX:yOVA5QDJyMx?=
MCF7 EV NV;kZ2k3TnWwY4Tpc44hSXO|YYm= NEPZR3kyOC1zMECg{txO MmDYNwKBkWh? NVTCUFhXTVSRUDDpcoR2[2W|IFHUUUBi[3SrdnH0bY9v MV[yOVA5QDJyMx?=
MCF7 BMI1 NGX0R2JHfW6ldHnvckBCe3OjeR?= NVvXd2NvOTBvMUCwJO69VQ>? M{jG[FLjiImq M2LKNGVVV1BiaX7keYNmeyCDVF2gZYN1cX[jdHnvci=> NYLpW2tIOjVyOEiyNFM>
HepG2 NImxPJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHyWnNFVVORwrC= M4DYfWlEPTB;M{CuNVbDqMLzwrCwMlUxyqEQvF2= MkHPNlUxPzh|MUG=
MOLT-3 NEj4Z5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TzfWROW00EoB?= Mlu4TWM2OD1yLkC1NeKhyrIEoECuNFAzyqEQvF2= NFPmb5QzPTB5OEOxNS=>
HT1080 NWPyVYpOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfpOpIyNTFyMDFOwG0> NWTsUWRCPC9{ND:0PEBp MUXEUXNQyqB? Ml:0bY5lfWOnczDj[YxtKGSnYYToJJNq\26rZnnjZY51dHliaX6gZUB3\XK7IHzve{Bkd26lZX70doF1cW:w NULJRVRxOjVyN{iwOlQ>
HT1080 NH;VZXJHfW6ldHnvckBCe3OjeR?= MVewMlAxODFvMUCwJO69VQ>? MnfINU0zPCCq MVHEUXNQyqB? NIPTNVdqdmS3Y3XzJJAueDV|KIPldlE2MSCrbjDic5RpKHSrbXWtJIFv\CClb37j[Y51emG2aX;uMYRmeGWwZHXueEBu[W6wZYK= NIjDWYUzPTB5OEC2OC=>
HT1080 NWr4T40{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzpSngxNjByMEGtNVAxKM7:TR?= M{LKd|I1KGh? MVTEUXNQyqB? NWr5PGFZ[2G3c3XzJIFvKGmwY4LlZZNmKGmwIITo[UBvfW2kZYKgc4Yh[2WubIOgbY4hTzJxTTyge4hqdGViZHXjdoVie2mwZzDTJIFv\CCJMTDwbIF{\SClZXzsdy=> M3e4WVI2ODd6ME[0
HD-MY-Z M4T3fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHmO28zPC92OD:3NkBp MYXJR|Ux97zgMUCwJO69VQ>? MWqyOVA1QDJ|Nh?=
DOHH-2 NWW3bpJnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vsWlI1KGh? M{PFUmlEPTExvK6xNFAh|ryP Mnq3NlUxPDh{M{[=
DOHH-2 NGrJSZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFH5[|U1QCCq MknFTWM2OD1zOT65xsDPxE1? M4nmSVI2ODR6MkO2
DOHH-2 NFqxPYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIn0c5k4OiCq NYSzT5d3UUN3ME21xsDPxE1? M3T5[FI2ODR6MkO2
REH NWH3OY9KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXGyOEBp MkXZTWM2OD1yLkCyO:Kh|ryP MVWyOVA1QDJ|Nh?=
REH NYTFcIxKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7U[ZQ1QCCq MnPpTWM2OD1yLkCxOOKh|ryP M{TsSlI2ODR6MkO2
REH NEPFSI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYP3R4g1PzJiaB?= MUjJR|UxRTBwMEG1xsDPxE1? NGDFVIUzPTB2OEKzOi=>
HH NEfuZnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LqVFI1KGh? NF:5SnBKSzVyPUGwOE44yqEQvF2= MlzjNlUxPDh{M{[=
HH MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPPOFghcA>? MlrPTWM2OD12OD62xsDPxE1? NGjGUnEzPTB2OEKzOi=>
HH MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TFbVczKGh? NHzhV4tKSzVyPUG0MlfDqM7:TR?= MWKyOVA1QDJ|Nh?=
HuT-78 M2DB[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;ydotyOjRiaB?= MnL5TWM2OD17LkRCpO69VQ>? M{jLeFI2ODR6MkO2
HuT-78 NUnOSnRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{ToeVQ5KGh? NUDY[YdoUUN3ME20MlPDqM7:TR?= MYOyOVA1QDJ|Nh?=
HuT-78 MljKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3m0cVczKGh? M3PzemlEPTB;ND6yxsDPxE1? MXWyOVA1QDJ|Nh?=
OPM-2 MlvFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXyyOEBp MnTqTWM2OD1{ND6xxsDPxE1? NYPXNY1EOjVyNEiyN|Y>
OPM-2 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnu0OFghcA>? MYTJR|UxRTUEoN88US=> M{juZlI2ODR6MkO2
OPM-2 MmjqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHpZWtLPzJiaB?= NHTlcY9KSzVyPUGuN:Kh|ryP MmD4NlUxPDh{M{[=
RPMI-8226 NFTEc5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUT4U|l2OjRiaB?= M1q5ZWlEPTB;MUC2MlbDqM7:TR?= Moi5NlUxPDh{M{[=
RPMI-8226 M4K1NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3f2d|Q5KGh? M4iyZWlEPTB;OUGuNeKh|ryP MnrNNlUxPDh{M{[=
RPMI-8226 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rjSVczKGh? M{jDWmlEPTB;MUSuPeKh|ryP MnfvNlUxPDh{M{[=
U-266 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVeyOEBp MXjJR|UxRTh4LkNCpO69VQ>? M3T3W|I2ODR6MkO2
U-266 NHTHO4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXu0PEBp M1TBWGlEPTB;NkiuOOKh|ryP M{DmW|I2ODR6MkO2
U-266 MoXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PtZ|czKGh? Ml;ZTWM2OD1{Nz60xsDPxE1? M37RWFI2ODR6MkO2
Kelly Mn3DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzTNE0yOCEQvF2= M1HKWFczyqCq NXjDUlBzUUN3ME2xMlUyQMLizszN NWDR[5lxOjVyMEi5NFA>
SH-SY5Y  MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvkUY4xNTFyIN88US=> Mm\EO|LDqGh? Mk[zTWM2OD1yLke1OOKh|ryPwrC= NHjXXpgzPTByOEmwNC=>
SK-N-AS M1m1bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nDOlAuOTBizszN MVy3NuKhcA>? NF\H[WRKSzVyPUGuO|EzyqEQvF5CpC=> M1\1U|I2ODB6OUCw
SK-N-DZ M1:4c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljyNE0yOCEQvF2= NELpfW84OsLiaB?= MUHJR|UxRTVwNEi1xsDPxE1? M1PvNVI2ODB6OUCw
HepG2 NXnkZYRzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXL5cnNoPDkEoHi= NXjE[VFXTE2VT9Mg MYDJR|UxRTF|Lk[1xsDDucLiMD65NuKh|ryP Mo\pNlQ6QTZzM{[=
A549 M{PPfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3j1WVQ5yqCq NWeyR3h4TE2VT9Mg MUHJR|UxRTJ2MT65xsDDucLiM{GuNlPDqM7:TR?= NWntS5FsOjR7OU[xN|Y>
MCF7 Mn7xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7nZmo{PDkEoHi= Mk\QSG1UV8Li NVrtTpZGUUN3ME24NU4xQcLiwsJCpFE1NjJzwrFOwG0> NWnEVYN[OjR7OU[xN|Y>
HL-60  MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV63NuKhcA>? M1HLNWlEPTB;MD6xNwKBjc7:TR?= M13oXlI1QTl|MEG0
HL-60[R] MonzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LLSVczyqCq M4rq[mlEPTB;Mz6xNwKBjc7:TR?= NWewT4dSOjR7OUOwNVQ>
MIAPACA NYHq[206T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrHTVUxRTFwMzFCtUAxNjB|IN88US=> Ml7YNlQ6PTN6MkG=
MCF-7 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zSSGdKPTB;MD6yOUDDuSByLkGg{txO MVeyOFk2Ozh{MR?=
HeLa Mk\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7VdYNIUTVyPUCuOlQhyrFiMD60JO69VQ>? MUKyOFk2Ozh{MR?=
MO59K  Ml\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLmO{Bl MWHJR|UxRTBwMUhihKXPxE1? M{XaPFI1QTV|NU[x
MO59J NHLpVVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnroO{Bl NX\VWGZ1UUN3ME2wMlHjiIYQvF2= NVTWTpE3OjR7NUO1OlE>
ME 180 M{n2dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfO[VVZPDkEoHlCpC=> NVzjeWdGUUN3ME24MlnDqMLzwrCwMlPjiIYQvF2= MnHQNlQ6PTNyMke=
MCF-7 M3OzPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLF[Zg4PDkEoHlCpC=> Mnq2TWM2OD1{Mz65JOKyKDBwM,MAie69VQ>? NYP5dItuOjR7NUOwNlc>
HeLa MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fDNlQ5yqCqwrC= NEPzfnRKSzVyPUSuO|EhyrFiMT605qCG|ryP M3fnNlI1QTV|MEK3
MDA-MB-453 M{DEPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfSXmg1PDkEoHlCpC=> M32wRWlEPTB;MUKuOUDDuSByLki15qCG|ryP MUmyOFk2OzB{Nx?=
MDA-MB-231 NF[yPGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF:1PIw1QMLiaNMg M3nv[WlEPTB;MkSuNlIhyrFiMj65OQKBjc7:TR?= Mlj1NlQ6PTNyMke=
PC-3 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7SO21[PDkEoHlCpC=> MWXJR|UxRTF2LkSgxtEhOy5{M,MAie69VQ>? NWjQUpFIOjR7NUOwNlc>
HT-29 Mn\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fKeFQ5yqCqwrC= M4DL[2lEPTB;MkGuOFUhyrFiMz64O-KBjc7:TR?= NUHxdJByOjR7NUOwNlc>
BGC-823 MmjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3f0bFQ5yqCqwrC= NITtelZKSzVyPUSzMlc1KMLzIEWuNVPjiIYQvF2= MVSyOFc6Ozh5Nx?=
HeLa NHvxeGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1i3SFQ5yqCqwrC= NFzsVXJKSzVyPUKwPU46OCEEsTCxN{41OiEkgJZOwG0> MXSyOFc6Ozh5Nx?=
A549 NUnNUVBWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHT5UXE1QMLiaNMg NYS3[Gx4UUN3ME2xN|kvPTRiwsGgO{4xPeLChd88US=> MnrZNlQ4QTN6N{e=
HK-2 NFHCWZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M36xTVQ5yqCqwrC= MkjtTWM2OD17LkG3JOKyKDFwNUlihKXPxE1? NYO2Tpo5OjR5OUO4O|c>

... Click to View More Cell Line Experimental Data

In vivo Etoposide administrated as a single agent is found to been ineffective in many xenografts growth, such as Heterotransplanted Hepatoblastoma NMHB1, and NMHB 2, [6] human neuroblastoma xenograft, [7] and human gastrointestinal cancer xenograft, [8] while the dose of 10 mg/kg i.p. Etoposide inhibits murine angiosarcoma cell ISOS-1 tumors in 36% of controls. [2] Etoposide induces tumor immunity in Lewis lung cancer. A single administration of 50 mg/kg Etoposide i.p., induces a 60% survival of C57B1/6 mice injected with Lewis lung cancer cell (3LL) over 60 days. About 40% of these surviving mice reject a subsequent challenge with 3LL, while none of control mice survive beyond 30 days. 3LL cells which have survived an 90% lethal concentration of Etoposide in vitro kill 75% of recipient mice, but 60% surviving mice reject challenge with 3LL. Splenocytes harvested from tumor rejecting mice protect naive mice injected with 3LL. [9]

Protocol

Kinase Assay:[5]
+ Expand

Topoisomerase II activity assay:

Nuclear extracts are prepared, and nuclei are isolated. The activity of topoisomerase II is calculated from the percentage of decatenation obtained. Tritiated kinoplast DNA (KDNA 0.22 μg) is used as a substrate. Etoposide and topoisomerase II are incubated for 30 min at 37 ℃ and are stopped with 1% sodium dodecyl sulfate (SDS) and proteinase K (100 μg/mL). The percentages of decatenation and inhibition of topoisomerase II by Etoposide are obtained.
Cell Research:[5]
+ Expand
  • Cell lines: Human glioma cell lines CL5
  • Concentrations: 80 μg/mL
  • Incubation Time: 1 hour
  • Method: After the Etoposide treatment, cells are removed from the dish with phosphate-buffered saline (PBS) containing 0.03% trypsin and 0.27 mM ethylenediaminetetraacetic acid (EDTA) and are diluted into culture dishes in appropriate numbers to yield between 20 and 200 colonies. After 12 days, cultures are fixed with methanol-acetic acid, stained with crystal violet, and scored for colonies containing more than 50 cells. The standard errors are typically less than 15% of the mean value unless otherwise stated.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Murine angiosarcoma xenografts ISOS-1
  • Formulation: Saline
  • Dosages: 10 mg/kg
  • Administration: i.p. every day for 5 days from day 7
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (169.9 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
5% DMSO+30% PEG 300+H2O
For best results, use promptly after mixing.
15mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 588.56
Formula

C29H32O13

CAS No. 33419-42-0
Storage powder
Synonyms VP-16, VP-16213

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03036904 Not yet recruiting Diffuse Large B-Cell Lymphoma|High Grade B-Cell Lymphoma Weill Medical College of Cornell University|Genentech, Inc.|Massachusetts General Hospital|M.D. Anderson Cancer Center February 6, 2017 Phase 1
NCT02432274 Recruiting Tumors|Solid Malignant Tumors|Osteosarcoma|Differentiated Thyroid Cancer (DTC) Eisai Limited|Eisai Inc. December 29, 2014 Phase 1|Phase 2
NCT02385110 Recruiting Leukemia M.D. Anderson Cancer Center September 23, 2015 Phase 2
NCT03007147 Not yet recruiting B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|BCR-ABL1 Fusion Protein Expression|Minimal Residual Disease|Philadelphia Chromosome Positive|T Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia Childrens Oncology Group|National Cancer Institute (NCI) July 2017 Phase 3
NCT03016871 Not yet recruiting CD (Cluster of Differentiation) 30-Positive Neoplastic Cells Present|Recurrent Hodgkin Lymphoma|Refractory Hodgkin Lymphoma City of Hope Medical Center|National Cancer Institute (NCI) June 2017 Phase 2
NCT03041311 Not yet recruiting Small Cell Lung Cancer G1 Therapeutics, Inc. May 2017 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Regarding the Etoposide S1225, do you have any data of the inhibition sepcificity of this product? It will inhibit other enzymes other than TOP2A?

  • Answer:

    According to the available published data, the inhibition of Etoposide is specific to TOP2A. But there're also two papers showing that Etoposide could inhibit the p34cdc2 Kinase Activity: 1. http://cancerres.aacrjournals.org/content/52/7/1817.short ; 2. http://cancerres.aacrjournals.org/content/50/12/3761.short.

Topoisomerase Signaling Pathway Map

Related Topoisomerase Products

Tags: buy Etoposide | Etoposide supplier | purchase Etoposide | Etoposide cost | Etoposide manufacturer | order Etoposide | Etoposide distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID